Juniper Biosciences

Executive Summary

Juniper Biosciences is a clinical-stage biopharmaceutical company pioneering targeted radiopharmaceuticals for cancer and other diseases. Founded in 2018 and headquartered in San Diego, the company leverages cutting-edge radioisotope science and high-specificity targeting ligands to develop theranostic agents—combining diagnostic imaging and targeted therapy. This approach aims to improve patient outcomes by enabling precise tumor localization and simultaneous treatment, addressing significant unmet medical needs in oncology. As a private entity, Juniper has not disclosed its total funding or valuation, but its focus on radiopharmaceuticals—a rapidly growing field with validated commercial success (e.g., Novartis' Lutathera and Pluvicto)—positions it within a highly attractive sector. The company's early clinical-stage status suggests lead programs are likely in Phase I or II trials, with potential for future data readouts and milestone-driven value inflection. While specific pipeline details are not publicly available, Juniper's presence in San Diego's biotech hub and its specialized focus indicate a disciplined approach to drug development.

Upcoming Catalysts (preview)

• Q4 2026Initial Phase I/II Clinical Data for Lead Radiopharmaceutical Candidate35% success
• H1 2027Strategic Partnership or Licensing Deal for Theranostic Platform20% success
• Q2 2026Series B or C Financing Round to Advance Pipeline60% success